Welcome to the path to your rebirth. We know that every journey is unique, but one thing is certain: it’s never too late to find harmony. Discover how to turn your past experiences into strength to build a balanced life, full of energy and inner peace.
Your journey to lasting health starts here.
Erreur lors de la traduction avec DeepL : Forbidden. You can find more info in our docs: https://developers.deepl.com/docs/getting-started/auth
12 December 2025
Erreur lors de la traduction avec DeepL : Forbidden. You can find more info in our docs: https://developers.deepl.com/docs/getting-started/auth
GLP-1 analogues: a major therapeutic advance in type 2 diabetes
11 November 2025
Understanding GLP-1 analogues: nature, mechanisms and specificities Over the past fifteen years, the GLP-1 analogue class has established itself as one of the mainstays of type 2 diabetes management. These substances, almost exact copies of the human incretin GLP-1 (Glucagon-Like Peptide-1), play a direct role in regulating carbohydrate metabolism. For example, exenatide – one of
GLP-1 analogues: principles and advances in the management of diabetes and obesity
11 November 2025
GLP-1 and incretins: physiological bases and mechanisms of action GLP-1 (glucagon-like peptide-1) belongs to the large family of incretins: these are digestive hormones, of which GLP-1 is distinguished by its production within the L cells of the intestine as soon as nutrients are detected. It should not be forgotten that this mechanism takes place after
GLP-1 analogues: understanding the new therapeutic levers and their challenges
11 November 2025
GLP-1 analogues: historical landmarks, scientific development and mechanisms of action The advent of GLP-1 analogues embodies a major turning point in the management of type 2 diabetes and obesity. It all began with the discovery of the biological role of the saliva of the Gila monster by Dr John Eng. This breakthrough led to the
GLP-1: therapeutic revolution or excessive hype? Current facts and issues
11 November 2025
What is GLP-1? From the laboratory to the patient: mechanisms and promises GlP-1 agonists (aGLP-1) today embody a decisive medical advance: they act at the interface of weight control and glycemic balance, relying on the incretin effect, the essential hormonal signal that regulates our energy balance. These molecules can now be found in the daily
When the hormone GLP-1 becomes a drug: the little-known effects and challenges of a medical revolution
11 November 2025
The medical rise of GLP-1 analogues: background, discoveries and promise The discovery of GLP-1 (glucagon-like peptide-1), an essential intestinal hormonal messenger in the management of glycemia and eating behavior, came to light in the late 1980s. This substance, released by the digestive tract just after food ingestion, stimulates insulin production while curbing glucagon production. Pioneers
GLP-1: From intestinal hormone to new therapeutic target for obesity
11 November 2025
Understanding GLP-1 and its physiological role GLP-1 (glucagon-like peptide-1) is a peptide hormone secreted by the gut when food is ingested. At the crossroads of metabolic pathways, it performs several key functions: regulating blood glucose by stimulating insulin secretion, slowing gastric emptying, and modulating the sensation of satiety – three elements that together participate in
The rise of GLP-1 agonists: a scientific response to the challenges of diabetes and obesity
11 November 2025
Understanding GLP-1 and its analogues: mechanisms and distinctive properties Glucagon-like peptide 1 (GLP-1) has established itself as a pivotal player in metabolic research and the pharmacological treatment of type 2 diabetes and obesity. This incretin hormone, secreted by intestinal L cells after each food intake, modulates blood glucose levels by stimulating insulin release from beta
Ozempic: understanding drugs, their uses and supervision
20 October 2025
Ozempic overview: definition, composition and presentation Ozempic is one of the major injectable treatments in the GLP-1 analog class, pharmacological reference A10BJ06. Developed by Novo Nordisk, it is aimed exclusively at adults with type 2 diabetes. Its active ingredient, semaglutide, is a synthetic peptide designed to mimic glucagon-like peptide-1 (GLP-1). This mechanism stimulates insulin secretion,
Stop Smoking Restorative Sleep: Effective Strategies for Better Sleep
2 May 2025
Sleep and smoking cessation: a silent crisis with alarming consequences The consequences of smoking cessation are not limited to the often-mentioned physical symptoms. A lesser-known facet, but just as destabilizing, is the disruption to sleep. Insomnia, nightmares or frequent awakenings: giving up smoking can become a real night-time ordeal. Why do these problems occur? And
